Literature DB >> 26854025

Deregulation of HOX genes by DNMT3A and MLL mutations converges on BMI1.

Y-T Tan1, Y Sun1, S-H Zhu1, L Ye2, C-J Zhao1, W-L Zhao1, Z Chen1, S-J Chen1, H Liu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26854025     DOI： 10.1038/leu.2016.15

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.

Authors:  Chi Wai So; Min Lin; Paul M Ayton; Everett H Chen; Michael L Cleary
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

2.  Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development.

Authors:  R D Hanson; J L Hess; B D Yu; P Ernst; M van Lohuizen; A Berns; N M van der Lugt; C S Shashikant; F H Ruddle; M Seto; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

Review 3.  DNMT3A in haematological malignancies.

Authors:  Liubin Yang; Rachel Rau; Margaret A Goodell
Journal:  Nat Rev Cancer       Date:  2015-02-19       Impact factor: 60.716

4.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

5.  Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells.

Authors:  J Yuan; M Takeuchi; M Negishi; H Oguro; H Ichikawa; A Iwama
Journal:  Leukemia       Date:  2011-04-29       Impact factor: 11.528

6.  DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells.

Authors:  Jie Xu; Yue-Ying Wang; Yu-Jun Dai; Wu Zhang; Wei-Na Zhang; Shu-Min Xiong; Zhao-Hui Gu; Kan-Kan Wang; Rong Zeng; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-04       Impact factor: 11.205

7.  MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein.

Authors:  Zhen-Biao Xia; Melanie Anderson; Manuel O Diaz; Nancy J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 11.205

8.  Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.

Authors:  Han Liu; Todd D Westergard; Amanda Cashen; David R Piwnica-Worms; Lori Kunkle; Ravi Vij; Can G Pham; John DiPersio; Emily H Cheng; James J Hsieh
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

9.  Cytokine-dependent granulocytic differentiation. Regulation of proliferative and differentiative responses in a murine progenitor cell line.

Authors:  M Valtieri; D J Tweardy; D Caracciolo; K Johnson; F Mavilio; S Altmann; D Santoli; G Rovera
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

10.  Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells.

Authors:  Lan-Lan Smith; Jenny Yeung; Bernd B Zeisig; Nikolay Popov; Ivo Huijbers; Josephine Barnes; Amanda J Wilson; Erdogan Taskesen; Ruud Delwel; Jesús Gil; Maarten Van Lohuizen; Chi Wai Eric So
Journal:  Cell Stem Cell       Date:  2011-06-03       Impact factor: 24.633
View more
  4 in total

1.  Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.

Authors:  Hamid Sayar; Yan Liu; Rui Gao; Mohammad Abu Zaid; Larry D Cripe; Jill Weisenbach; Katie J Sargent; Mehdi Nassiri; Lang Li; Heiko Konig; Attaya Suvannasankha; Feng Pan; Rajasubramaniam Shanmugam; Chirayu Goswami; Reuben Kapur; Mingjiang Xu; H Scott Boswell
Journal:  Oncotarget       Date:  2017-12-25

2.  Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations.

Authors:  Li Yang; Ke'Feng Shen; Mei'Lan Zhang; Wei Zhang; Hao'Dong Cai; Li'Man Lin; Xiao'Lu Long; Shu'Gang Xing; Yang Tang; Jie Xiong; Jia'Chen Wang; Deng'Ju Li; Jian'Feng Zhou; Min Xiao
Journal:  Front Oncol       Date:  2019-10-24       Impact factor: 6.244

3.  Identification of distinct loci for de novo DNA methylation by DNMT3A and DNMT3B during mammalian development.

Authors:  Masaki Yagi; Mio Kabata; Akito Tanaka; Tomoyo Ukai; Sho Ohta; Kazuhiko Nakabayashi; Masahito Shimizu; Kenichiro Hata; Alexander Meissner; Takuya Yamamoto; Yasuhiro Yamada
Journal:  Nat Commun       Date:  2020-06-24       Impact factor: 14.919

4.  Allogenic Stem Cell Transplantation Abrogates Negative Impact on Outcome of AML Patients with KMT2A Partial Tandem Duplication.

Authors:  Gabriel Antherieu; Audrey Bidet; Sarah Huet; Sandrine Hayette; Marina Migeon; Lisa Boureau; Pierre Sujobert; Xavier Thomas; Hervé Ghesquières; Arnaud Pigneux; Mael Heiblig
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.